VIVOS INC (RDGL) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US92858K2042

Price
0.05 USD
Market cap
22.59 m USD
P/E (2025)
–
P/S (2025)
330.30
Dividend yield
0.00 %
Net margin
-4,483.86 %
Return on equity (ROE)
-184.61 %
Return on assets (ROA)
-164.17 %

VIVOS INC financials

Fiscal year20242025
Revenue27,995.00 USD68,379.00 USD
Gross profit-2,984.00 USD-59,755.00 USD
Operating income-2.60 m USD-3.17 m USD
EBIT-2.91 m USD-3.07 m USD
Net income-2.91 m USD-3.07 m USD
Diluted EPS – continuing operations-0.01 USD-0.01 USD

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About VIVOS INC

Vivos Inc., a radiation oncology medical device company, engages in the development of yttrium-90-based precision radionuclide therapy devices for the treatment of non-resectable tumors in the United States. The company develops RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. It is also developing PLGA-g-PEG polymers; PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents; Duncan Chiller, a general laboratory equipment for non-water localized chilling; and other products under the Alpha-Gel, Beta-Gel, Gamma-Gel, and Peltier Chiller brands. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Kennewick, Washington.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.